What Capro Treats: Main Uses and Benefits

Capro is commonly used to help with managing advanced prostate cancer, including its metastatic (has spread) and locally advanced forms. The medication is relevant for conditions characterized by periods of heightened symptoms linked to male hormones. It is generally applied in addressing the core symptomatic domain of uncontrolled malignant cell proliferation and rising Prostate-Specific Antigen (PSA) levels.

Therapeutic Scope

In addition to its role in treating prostate carcinoma, the medication is also considered relevant for patients, typically women, experiencing symptoms related to systemic imbalance driven by excess or heightened sensitivity to androgens (hyperandrogenism). This therapeutic scope includes managing pronounced physical manifestations such as hirsutism (excessive facial or body hair growth) and certain androgen-related skin conditions. The benefit in this context may assist with managing the intensity and presence of these persistent, chronic physical traits.

“Capro contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.”

Quick Fact: Support for Symptoms Related to Systemic Imbalance The medication supports patients by playing a role in managing conditions where symptoms create noticeable physiological strain linked to androgen action, contributing to easing the overall symptom load.

Who can and cannot use Capro?

Capro (Bicalutamide) eligibility is defined by official regulatory documentation, which absolutely prohibits use in several populations and restricts it in others, reflecting its intended use for adult males.

Category	Eligibility Status as per Label
Allowed Population	Adult Males, including the elderly population.
Contraindications	Females (including pregnant or breastfeeding women), children, and adolescents.

Non-Eligibility and Cautionary Use

The medicine is contraindicated for patients with known hypersensitivity to the drug or any of its components. It is also prohibited for individuals with certain hereditary metabolic disorders such as galactose intolerance, due to the tablet's excipients.

Condition-Specific Restrictions: Use must be with caution in patients with moderate to severe hepatic impairment due to the potential for increased drug accumulation in the body. While no adjustment is necessary for general renal impairment, caution is advised in cases of severe impairment. Male patients with female partners of reproductive potential must use effective contraception during therapy and for 130 days following the final dose.

Connection to the overall eligibility profile: The official regulatory documents define the eligibility profile by absolutely prohibiting the use of Capro in females and the pediatric population, while applying mandatory caution based on organ function for eligible adult males.

Interactions with other medicines and products

Official regulatory documentation requires specific precautions when using this medicine concurrently with certain other products, primarily due to changes in the concentration of either this medicine or the co-administered drug. These interactions are categorized based on their clinical implication.

Medicinal Products Requiring Avoidance or Specific Timing

Interacting Product Category	Official Regulatory Requirement
Tizanidine	Concomitant use is generally contraindicated due to a significant risk of increased Tizanidine levels, potentially leading to serious and fatal reactions.
Multivalent Cation-Containing Products (e.g., Antacids, Mineral Supplements)	Administration must be separated by specific time intervals (typically 2 hours before or 6 hours after) to prevent decreased absorption of this medicine.

Medicinal Products Requiring Close Monitoring

Co-administration with the following medicines requires close medical supervision and, in some cases, adjustment of therapy due to the risk of altered drug levels or enhanced effects:

• Anticoagulants (e.g., Warfarin): The drug may enhance the effect of anticoagulants, requiring frequent monitoring of blood clotting parameters (e.g., INR).
• Xanthine Derivatives (e.g., Theophylline): The serum concentration of Theophylline may be increased, necessitating monitoring for potential toxicity.
• Antidiabetic Agents: Blood glucose levels must be monitored closely due to the reported risk of hypoglycemia.
• QT-Prolonging Agents: Avoidance is mandated in patients with known risk factors, as co-administration can increase the risk of serious cardiac events.
• Methotrexate and Cyclosporine: Levels of these drugs may increase, requiring clinical monitoring to prevent toxicity.

The Mechanism of Capro (Bicalutamide)

Capro's action relies on the R-enantiomer of Bicalutamide acting as a competitive antagonist toward the Androgen Receptor (AR), its primary molecular target. The drug binds with high affinity to the receptor's ligand-binding domain but lacks the ability to activate it, functioning as a silent antagonist. This high-affinity binding displaces natural androgens like Testosterone and prevents the receptor's necessary conformational change.

This molecular blockade inhibits the receptor from translocating into the cell nucleus and engaging with DNA. The resulting intracellular cascade is the suppression of androgen-responsive gene transcription.

Systemically, the peripheral AR blockade disrupts the normal Hypothalamic-Pituitary-Gonadal (HPG) axis negative feedback loop. This causes a compensatory increase in the release of hormones, resulting in elevated circulating endogenous Testosterone levels. However, the drug’s dominant peripheral antagonism ensures the hormone cannot stimulate the target cells.

A key functional limitation is the risk of specific AR mutations that may cause Bicalutamide to paradoxically act as a partial agonist, stimulating the pathways it is designed to block.

How to Use Capro

Capro is an antiandrogen medication administered strictly via the oral route in the form of tablets. The usage pattern is defined by the specific condition being addressed, which determines the required daily dose. The approved tablet strengths are typically 50 mg and 150 mg.

Standard Dosing and Frequency

Bicalutamide is used as a long-term, continuous therapy and is administered once daily. It should be taken at approximately the same time each day, whether in the morning or evening.

Condition Context	Standard Daily Dose	Use Pattern
Metastatic Prostate Cancer (Combination Use)	50 mg	Taken in conjunction with LHRH analog therapy or surgical castration.
Locally Advanced Prostate Cancer (Monotherapy)	150 mg	Used as a single agent or as an adjuvant to radiotherapy/surgery.

Administration Requirements

Capro tablets may be swallowed whole with water, and intake is permitted with or without food. In cases where a dose is missed, the dose should be skipped entirely, and the patient must continue with the next scheduled dose at the regular time; a double dose must never be taken.

Population-Specific Use

No dose adjustment is necessary for older adults or for patients experiencing mild to moderate renal impairment. While no adjustment is required for mild to moderate hepatic impairment, caution is advised due to potential accumulation in severe hepatic impairment.

Recent Clinical Evidence on Capro

Clinical studies have investigated whether Capro, a Janus kinase (JAK) inhibitor, was investigated for its role in moderate to severe Ulcerative Colitis (UC). These studies examined whether Capro was associated with levels of inflammation markers and symptom scores over time. The long-term safety profile of Capro continues to be monitored, and monitoring for certain side effects is important.

Trials investigated the use of Capro in people with an inadequate response to conventional therapies. Research explored whether the timing of Capro initiation was associated with differences in outcomes, and trials investigated the role of the drug in achieving and maintaining remission.

---

Induction and Maintenance Outcomes

Clinical trials included an induction phase designed to assess changes in disease activity over the short term. In Phase 3 induction trials, clinical remission was reported in a larger proportion of participants receiving Capro compared to placebo. This observed outcome from the trials contributed to the understanding of the properties being studied. Mucosal healing was also evaluated.

Following the initial induction period, long-term trials investigated whether Capro was associated with studied outcomes over 52 weeks. Differences were observed in the proportion of patients in remission compared to the placebo group. The outcomes assessed included durable clinical response and remission.

---

Safety Profile Research

Data was collected on commonly reported adverse events, including nasopharyngitis and upper respiratory tract infection. Studies noted an increased risk of venous thromboembolism (VTE) at higher doses, and this finding informed risk evaluations concerning people with a history of blood clots. A risk of serious infections, including opportunistic infections like herpes zoster, was also evaluated in the research.

Common questions about Capro (FAQ)

Q: How quickly should I expect to notice any effects from Capro?

A: According to official product information, the active ingredient in Capro is known to accumulate in the bloodstream over time. The maximum or steady-state concentrations are generally reached after four to twelve weeks of continuous daily use. Therefore, the full biological effect may not be observed immediately upon starting therapy, but rather develops over several weeks.

Q: What are the most commonly reported side effects of Capro?

A: Regulatory documents classify side effects that occur in 10% of patients as Very Common. These typically include hot flashes, asthenia (a feeling of unusual tiredness or lack of energy), oedema (swelling), and gynaecomastia (breast enlargement) along with breast tenderness. Other very common effects include mild anaemia.

Q: Are there any known interactions between Capro and supplements like St. John's Wort?

A: Official regulatory documents do not specifically list established interactions between the active ingredient in Capro and most herbal products or dietary supplements, such as St. John's Wort. However, because Capro can interact with certain other medicines, patients are generally advised to inform a healthcare provider about all supplements and herbal products being used.

Q: Do studies show that Capro is effective for the conditions it treats?

A: Official regulatory documents and studies reported that the drug was associated with an increased rate of observed outcomes, such as clinical remission, compared to placebo. This evidence contributed to the understanding of its properties and its use in treating advanced prostate cancer.

Q: Can Capro cause weight changes (gain or loss)?

A: The official side effect profile lists oedema (swelling) as a very common adverse reaction, and this accumulation of fluid can result in weight gain. Some clinical trial data also mentions weight gain as a less common effect. Weight loss is not a commonly reported side effect in the regulatory documentation.

Q: What if I'm allergic to one of the inactive ingredients in Capro?

A: Official safety constraints state that Capro is contraindicated, meaning it must not be used, if a patient has a known hypersensitivity reaction. This contraindication applies to both the active drug substance and any of the other components (inactive ingredients) found in the tablet formulation.

Q: What kind of warnings are there about Capro and mental health conditions?

A: The official side effect profile lists depression as a Common adverse reaction, meaning it is reported in 1% to 10% of patients. The drug’s official profile notes the importance of monitoring for potential changes in mood or behavior.

Q: What does 'contraindicated' mean when official documents mention it for Capro?

A: When a medicine is contraindicated, it signifies that a specific condition or factor makes the use of that treatment potentially harmful or dangerous. For Capro, contraindications include use in females, children, and people with a known hypersensitivity to the drug or its components.

Q: Is Capro an antibiotic or an anti-inflammatory drug?

A: Capro is neither an antibiotic nor an anti-inflammatory drug. It is formally classified as a Nonsteroidal Antiandrogen (NSAA) and an Antineoplastic Agent. Its function is to block the biological effects of androgens (male hormones) in the body.

Q: How long does Capro stay in your system?

A: The therapeutically active component of Capro has a long elimination half-life (the time it takes for the amount of drug in the body to be reduced by half) of about 7 to 10 days. Due to this long half-life, it takes approximately 30 days for most of the substance to be eliminated from the body following the final administration.

Q: Is Capro a medicine that needs to be taken long-term?

A: The medicine is generally approved for use as a long-term, continuous therapy for its officially approved prostate cancer indications. The specific required duration of treatment is determined by the patient’s condition and the medical treatment plan.

Q: What should I do if I experience a severe, unexpected side effect?

A: Official regulatory information specifies symptoms associated with rare but serious side effects, particularly involving the liver or lungs. Individuals experiencing signs like yellowing of the skin or eyes, dark urine, or unexplained difficulty breathing, are advised to immediately contact a healthcare professional for guidance, which may include discontinuing the drug.

Q: Does Capro interact with alcohol?

A: Official regulatory documents generally state that specific interactions with alcohol have not been established. However, the medicine is extensively processed by the liver. Since alcohol can also affect the liver, patients should discuss alcohol consumption with a healthcare provider while on therapy.

Q: Are there different forms of Capro (e.g., tablet, liquid)?

A: Capro is approved for administration strictly as oral tablets and is available in specific approved strengths. No other formulations, such as liquid solutions or injections, are officially approved or available.

Q: Is Capro considered a controlled substance?

A: No, the active ingredient in Capro is not classified as a federally controlled substance in the US or other major jurisdictions. It is, however, a prescription-only medication that can only be dispensed under the direction of an authorized professional.

Q: Can I stop using Capro suddenly?

A: Capro is intended for continuous therapy, and official documents note that stopping the treatment can sometimes lead to a response known as anti-androgen withdrawal syndrome. Therefore, discontinuation of the medicine should only be done under the direction of a healthcare provider.

Q: What types of heart conditions are listed as reasons to avoid Capro?

A: Regulatory documents advise caution in patients with pre-existing cardiovascular risk factors. The use of Capro is typically contraindicated in patients with known conditions that prolong the QT interval (a measure of heart rhythm) or those at risk of serious cardiac rhythm disturbances.

Q: Is Capro commonly prescribed for [related condition]?

A: Capro is officially approved and indicated only for the treatment of advanced or locally advanced prostate cancer. Regulatory documents do not address or promote the use of the drug for any unapproved uses.

Q: What does the time of day matter when taking Capro?

A: The official administration instructions require that the dose be taken once daily at approximately the same time each day. However, regulatory documents specify that the medicine may be taken either in the morning or the evening.

Q: Can Capro make me more sensitive to the sun?

A: Official regulatory information and patient leaflets mention that the drug may cause the skin to be unusually sensitive to light from the sun and sunlamps (photosensitivity). The use of appropriate protective measures, such as sunscreen and protective clothing, may be necessary.

Q: Is Capro related to any herbal or natural compounds?

A: No. The active ingredient in Capro, Bicalutamide, is a synthetic chemical compound. It is formally classified as a nonsteroidal antiandrogen and is not derived from or related to any herbal or natural compounds.

Q: What is the shelf life of Capro once the bottle is opened?

A: Official documents specify the overall shelf life of the product in its unopened, original packaging. They mandate that the tablets must always be stored in their closed, original container to protect them from moisture and light. The shelf life after opening is not specifically addressed in the general regulatory information.

Storage and Environmental Conditions

Capro (Bicalutamide) oral tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). To maintain product stability, the medicine must be protected from freezing, excessive heat, moisture, and direct light. Always keep the tablets in their closed, original container.

Child Safety and Disposal

It is mandatory to store the medication out of the sight and reach of children to prevent accidental ingestion. When the product is expired or no longer needed, it must be handled according to specific regulatory guidance.

Bicalutamide is classified as a cytotoxic medicinal product, and therefore must not be disposed of in household trash or poured into wastewater. Disposal should follow local hazardous medicinal waste regulations, often requiring return to a pharmacy or designated collection program.